



INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH

Inclusion in Web of Science (Thomson Reuters) - ESCI

Projected Impact Factor (2017): 0.59 , SJR (2017): 0.137

Five-Year Projected Impact Factor: 1.83


[Editorial Board](#) [Current Issues](#) [Archives](#) [Instructions to Authors](#) [Manuscript Submission](#) [Conference Proceedings](#)
[Home](#) [Volume 9 \(2018\) - Issue 2, February](#)

Volume 9 (2018) - Issue 2, February

[Archive](#) [Most Popular](#) [Most Cited](#)

REVIEW ARTICLES

Title	Views	PDF	Cited
<p>1. NEW ADVANCEMENTS OF BIOPLASTICS IN MEDICAL APPLICATIONS</p> <p>The bio-plastics that are produced either from fossil material or can be synthesized from biomass or renewable resources, such as Poly-lactic acid (PLA), Polyethylene glycol (PEG) and Poly - ε - caprolactone (PCL) are been reported as a material of choice for biomedical applications due to their good physical properties such as crystallinity, storage modulus, glass transition temperature and bior...</p> <p>K. Bano, R. Pandey, Jamal-e-Fatima and Roohi* <i>Protein Research Laboratory, Department of Bioengineering, Integral University, Lucknow, Uttar Pradesh, India.</i> DOI: 10.13040/IJPSR.0975-8232.9(2).402-16</p> <p>Abstract HTML Full Text PDF Citation</p>	2580	863	0
<p>2. AN OVERVIEW OF DANDRUFF AND NOVEL FORMULATIONS AS A TREATMENT STRATEGY</p> <p>This review gives an insight of the scalp condition- dandruff which affects more than 50% of the human population. Malassezia furfur is reported as the main cause of dandruff. This article aims at investigating other causes of dandruff which include microbial and non - microbial factors. These factors have been explained in this article. It also highlights the various treatment options and newer f...</p> <p>M. Narshana* and P. Ravikumar <i>Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, Maharashtra, India.</i> DOI: 10.13040/IJPSR.0975-8232.9(2).417-31</p> <p>Abstract HTML Full Text PDF Citation</p>	2622	877	0
<p>3. MEDICINAL USE OF AN ANCIENT HERB MOMORDICA CYMBALARIA: A REVIEW</p> <p>Momordica cymbalaria (Hook, Fenzl) is a vine of Momordica genus found in the Indian states of Karnataka, Madhya Pradesh, Maharashtra, Andhra Pradesh and Tamil Nadu. The medicinal herb also been named Luffa tuberosa (Roxb) or Momordica tuberosa (Roxb). Momordica cymbalaria is commonly known as Karchikai (Kannada) or Athalakkai (Tamil) or Kasarakayee (Andhra Pradesh) and Kakrol (India). Momordica cy...</p> <p>D.K. Jha*, R. Koneri and S. Samaddar <i>Department of Pharmacology, Karnataka College of Pharmacy, Bangalore, Karnataka, India.</i> DOI: 10.13040/IJPSR.0975-8232.9(2).432-41</p> <p>Abstract HTML Full Text PDF Citation</p>	1756	554	0
<p>4. MITOCHONDRIA - TARGETED ANTIOXIDANT: AGING</p>	2243	460	0

The mitochondrion, the "power house of cell", plays a central role in energy-generating processes so called as "master of life and death". A decline in mitochondrial function plays a key role in the aging process and increases the incidence of age-related disorders. With advanced age, mitochondrial DNA volume, integrity and functionality decrease due to accumulation of mutations and ...

B. Varghese*, N. L. Gowrishankar, K. Drisya and M. T. Ramees
Department of Pharmaceutical Analysis, Prime College of Pharmacy,
Palakkad, Kerala, India.

442-455

DOI: 10.13040/IJPSR.0975-8232.9(2).442-55

[Abstract](#) [HTML Full Text](#) [PDF](#) [Citation](#)

5. AN UPDATED PHARMACOLOGICAL ACTIVITY OF COCCINIA INDICA (WIGHT & ARN.) 1423 460 0
- Traditional system of medicine consists of large number of plants with various medicinal and pharmacological importances and hence represents a priceless tank of new bioactive molecules. Coccinia indica belongs to the family Cucurbitaceae. It is a rapidly growing, perennial climber or trailing vine. Traditionally different parts of this plant namely the roots, leaves and fruits are used in folklor...

M. Kumar*, S. Alok, D. K. Chanchal, R. K. Bijauliya, R. D. Yadav and M. Sabharwal
Department of Pharmacognosy, Institute of Pharmacy, Bundelkhand
University, Jhansi, Uttar Pradesh, India.

456-465

DOI: 10.13040/IJPSR.0975-8232.9(2).456-65

[Abstract](#) [HTML Full Text](#) [PDF](#) [Citation](#)

RESEARCH ARTICLES

- | Title | Views | PDF | Cited |
|---|-------|-----|-------|
| 6. DESIGN AND EVALUATION OF CHITOSAN-BASED MICROPARTICLES AS MODELS OF PROTEIN DELIVERY SYSTEMS
Controlled release systems for protein and peptide vaccines based polymers have been considered for many applications in medical therapies. Chitosan is non-toxic and easily absorbed biopolymers and is often used in many researches to sustained release drugs and proteic vaccines. This study investigates the kinetics of release in vitro of bovine serum albumin (BSA) from chitosan microparticles and ...
L. V. Barros-Lima, M. E. F. A. G. Oliveira and R. V. S. Amorim*
Programa de Pós-graduação em Morfotecnologia - Departamento de Histologia e Embriologia - UFPE, Centro de Biociências - Cidade Universitária, Recife, PE, Brazil.
DOI: 10.13040/IJPSR.0975-8232.9(2).466-74 | 1054 | 429 | 0 |
| 7. T-CELL ACTIVATION CONTROLLING EFFECTS OF ETHYL ACETATE FRACTION OF KALANCHOE PINNATA (LMK) PERS ON TMPD-TREATED LUPUS MICE
T-cell activation, with the low expression of CD62L (L-selectin) marker in the spleen, will increase B cell activity to produce lupus antibodies. Therefore, lupus patients need drugs which could increase the L-selectin expression in the spleen to reduce the auto-reactive T cell. The tested drug to increase the L-selectin in this research was the ethyl acetate fraction of Kalanchoe pinnata (Lmk) P...
N. Indriyanti, J. Soeroso and J. Khotib*
Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga, Jl. Dharmawangsa Surabaya, Indonesia.
DOI: 10.13040/IJPSR.0975-8232.9(2).475-82 | 986 | 386 | 0 |
| 8. EVALUATION OF HISTO-PATHOLOGICAL CHANGES IN THE MICE EXPOSED TO SODIUM NITRITE FOR LONG TERM BY USING HEMATOXYLIN AND EOSIN STAINING
Objective: The aim of this study is to investigate whether exposure to subclinical dose of sodium nitrite for long term can trigger histopathological changes which are able to detect by using hematoxylin and eosin stain. Sodium nitrite has various properties that make it widely used in industrial and pharmaceutical fields. Method: Three groups of mice were used in this study; the first group was...
S. M. A. Al-Hiti*, A. H. M. Hussain and A. A. F. Al-Zabaidy
Department of Pharmacology and Toxicology, Pharmacy College, University of Baghdad, Iraq.
DOI: 10.13040/IJPSR.0975-8232.9(2).483-89 | 969 | 365 | 0 |



Received on 17 May, 2017; received in revised form, 17 July, 2017; accepted, 25 July, 2017; published 01 February, 2018

T-CELL ACTIVATION CONTROLLING EFFECTS OF ETHYL ACETATE FRACTION OF *KALANCHOE PINNATA* (LMK) PERS ON TMPD-TREATED LUPUS MICE

Niken Indriyanti^{1,2}, Joewono Soeroso³ and Junaidi Khotib^{*4}

Department of Pharmacology¹, Faculty of Pharmacy, Mulawarman University, Samarinda, East Kalimantan - 75119, Indonesia.

Faculty of Pharmacy², Universitas Airlangga, Jl. Dharmawangsa Surabaya, East Java - 60115, Indonesia.

Department of Internal Medicine³, Faculty of Medicine, Universitas Airlangga, Jl. Prof. Dr. Moestopo Surabaya, East Java - 60115, Indonesia.

Department of Clinical Pharmacy⁴, Faculty of Pharmacy, Universitas Airlangga, Jl. Dharmawangsa Surabaya, East Java - 60115, Indonesia.

Keywords:

T cell activation, Ethyl acetate fraction of *Kalanchoe pinnata* (Lmk) Pers, L-selectin, Leukocyte, Lupus

Correspondence to Author:

Junaidi Khotib

M. Kes., Ph.D., Apt,
Faculty of Pharmacy, Universitas
Airlangga, 4 - 6 Airlangga Road,
Surabaya - 6 0115, Indonesia.

E-mail: junaidi-k@ff.unair.ac.id

ABSTRACT: T-cell activation, with the low expression of CD62L (L-selectin) marker in the spleen, will increase B cell activity to produce lupus antibodies. Therefore, lupus patients need drugs which could increase the L-selectin expression in the spleen to reduce the auto-reactive T cell. The tested drug to increase the L-selectin in this research was the ethyl acetate fraction of *Kalanchoe pinnata* (Lmk) Pers leaves (EF-KP), based on its immunosuppressant and anti-inflammatory activities. The research was performed by means of 2, 6, 10, 14 tetramethylpentadecane (TMPD) induced lupus-like mice. The experimental groups consisted of negative control (NC), EF-KP, and positive control (PC) groups. After 21 day treatment, the blood leukocyte was checked. Then, the spleen was prepared for the flow cytometry method to measure CD4⁺CD62L⁺ and CD8⁺CD62L⁺ T cells. The relative percentage of CD4⁺CD62L⁺ T cells in EF-KP groups increased insignificantly ($p > 0.05$) (NC = $7.91 \pm 4.98\%$, EF-KP = $8.63 \pm 3.07\%$, PC = $12.62 \pm 8.09\%$). The relative percentage of CD8⁺CD62L⁺ T cells increased significantly ($p < 0.05$) (NC = $6.20 \pm 4.91\%$, EF-KP = $15.94 \pm 9.37\%$, PC = $24.32 \pm 17.47\%$). Additionally, the total leukocytes reduced significantly ($p < 0.05$) (NC = 6.333 ± 1.078 cells/mm³, EF-KP = 4.967 ± 635 cells/mm³, PC = 4.367 ± 1.102 cells/mm³). The results show that the active compounds in the EF-KP can mainly control the L-selectin regulatory function of CD8⁺ T cells, and then reduce the inflammation process with the point view of reducing its total leukocytes. At last, the main compounds in the EF-KP could control the T-cell activation in lupus.

INTRODUCTION: T cell and B cell activation induces B cells to increase the production of lupus-specific antibodies^{1,2}.

T cell activation is regulated by L-selectin or CD62L as an activation marker. The L-selectin expressed on naïve CD4 T cells is needed for the recirculation between blood and lymph node. The L-selectin is an adhesion molecule that is able to reduce lymphocytes and bind the endothelial venule ligand. This regulation is important to control the traffic of T lymphocyte circulated to peripheral lymph node³⁻⁸. The naïve T cells in the spleen binds L-selectin, and then the L-selectin will

	<p>QUICK RESPONSE CODE</p>
	<p>DOI: 10.13040/IJPSR.0975-8232.9(2).475-82</p>
<p>Article can be accessed online on: www.ijpsr.com</p>	
<p>DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.9(2).475-82</p>	

be shedded in the circulation become the memory T cells^{9, 10}. The low number of L-selectin in the spleen will increase the lupus severity since the high number of T effector, some of them are auto-reactive, cannot be handled results in inflammation.

This severity can be inhibited by using lupus standard treatment. Lupus treatment by rheumatologists is sufficient to increase the quality of life, but it is not in an optimal outcome^{11, 12}. Most of the drugs used are off-label nonselective immunosuppressive drugs, such as cyclophosphamide, methotrexate, azathioprine, and mycophenolate mofetil that are very toxic in a long term use¹³⁻¹⁶. Many efforts are performed to obtain new lupus drugs which are effective, safe, and acceptable. Many biotechnology manipulations are performed to find the appropriate treatment¹⁴⁻¹⁷, but it needs high cost. The other effort is to find new lupus drugs from potential medicinal plants based on its immunosuppressive effect. However, medicinal plants have multiple effects which can beneficially use to reduce lupus manifestations. In this research, we try to exploit the multiple effects of *Kalanchoe pinnata* (Lmk) Pers leaves to increase the L-selectin in the spleen of in TMPD-treated lupus mice.

According to our previous study, the aqueous extract of *Kalanchoe pinnata* (Lmk) Pers leaves can reduce the kidney structural damage of TMPD-treated lupus mice. The main flavonoid compounds (mainly found in the ethyl acetate fraction) of this plant are active as immunosuppressant, anti-inflammatory, and antioxidant¹⁸⁻²¹. The flavonoids of *Kalanchoe pinnata* (Lmk) Pers also inhibit T cell mitogenesis²². Besides, it inhibits IL-2 and IL-4 production without cell toxicity. *Kalanchoe pinnata* (Lmk) Pers is not toxic²³ and also safe for maternity since it reduces the uterine contractility²⁴. This "miracle plant" is widely used as traditional in Africa and Bangladesh for many purposes^{25, 26}.

Based on many benefits of *Kalanchoe pinnata* (Lmk) Pers leaves for lupus, this research provide the data of the effects of flavonoids in the ethyl acetate fraction of *Kalanchoe pinnata* (Lmk) Pers (EF-KP) leaves in maintaining the L-selectin number in the spleen of lupus mice. The high number of L-selectin in spleen will control the excessive T cell activation in lupus. It could

prevent the spread of circulating L-selectin, and then inhibit the systemic inflammation. The high level of leukocyte as an inflammatory outcome found in lupus model would be reduced if the L-selectin regulation was maintained well. Therefore, this research focused on the effect of flavonoids in the ethyl acetate fraction of *Kalanchoe pinnata* (Lmk) Pers (EF-KP) on L-selectin number in the spleen of TMPD-treated lupus mice.

MATERIALS AND METHODS:

Materials: The *Kalanchoe pinnata* (Lmk) Pers fresh leaves were obtained from a cultivation farm at Trenggalek, East Java. The botany identity of this plant was performed by the Conservation Unit of Indonesian Institute of Science, Purwodadi with the identification number of 0284/IPH.06/HM/II/2015.

The female Balb/c mice (80 mice) aged 4 weeks were received from LPPT Gadjah Mada University, Indonesia. These mice were pathogen free species with the certificate number of 352/LP3HP/29/VII/2015. They were housed, randomized, and handled using standard maintenance on the Guide of the Care and Use of Laboratory Animal 8th edition, published by National Research Council 2011²⁷.

TMPD >98% purity (Pristane) with the code number of Sigma-P2870 was obtained from Sigma-Aldrich supplier in Singapore. Anti-CD4, anti-CD8, and anti-L-selectin antibodies were obtained from Biogenesis, USA. Turk reagent, PBS, and aquadest were obtained from the laboratory of Faculty of Pharmacy, Universitas Airlangga. The chemicals used in the fractionation, *i.e.* ethyl acetate pro analysis, were obtained from Merck through PT. Dianum as Indonesian supplier. The chemicals used in the profiling were obtained from Biotechnology Laboratory of PUSPIPTEK Serpong, Indonesia.

Methods: The EF-KP was obtained by using a method used on the previous study. The ethyl acetate fraction quality control test was performed by quantitation of one active marker, rutin (a flavonoid compound), by means of LC-MS/MS system. The female Balb/c mice used were 7 weeks old when treated using 0.5mL TMPD. The administration was intraperitoneal injection.

The induction time was lasted for 6 months²⁸⁻³¹. At the end of the induction time, the proteinuria semi quantitative data showed a severe lupus manifestation. Then, the 30 mice were divided into 3 experimental groups, *i.e.* the negative control group that consists of lupus mice that received placebo, the EF-KP group that received the EF-KP at a dose which comparable to 400 mg/kgBB of crude extract, and the positive control group that received cyclophosphamide at a dose of 1 mg/kgBW. The compounds tested were orally administered on the daily treatment until 21 days.

Finally, the mice were sacrificed. The blood was prepared as a sample for total leukocyte count (TLC) assay by means of hemocytometer Neubauer-improved and inverted microscope Olympus CKX41. The fresh spleen of each mouse was prepared to be spleen cells that were ready for flow cytometry assay. The T regulatory cells (T regs) CD4⁺L-selectin⁺ and CD8⁺L-selectin⁺ were measured by using flow cytometer BD FACS Calibur. Then, the data was analyzed by using BD Cell Quest program.

All of the data was analyzed by facilitating of One way ANOVA by means of SPSS Statistics (version 22). The ethical clearance of this research was approved by local ICUC of Veterinary Medicine Faculty of Universitas Airlangga at January 12, 2016, with the certificate number of 526-KE, then the research performed until April, 2017.

RESULTS:

The EF-KP Quality Control: The aqueous extract of *Kalanchoe pinnata* (Lmk) Pers was made from the fresh leaves. The extract was lyophilized and then fractionated by using liquid-liquid extraction. The EF-KP profile was measured by using LC/MS/MS tandem system. The result is shown in **Fig. 1**. According to the profile, the rutin is in the retention time of 2.90. The linearity of the rutin standard used for the rutin calculation in the EF-KP sample is shown in **Fig. 2**. Based on the standard, the rutin concentration in the EF-KP is in **Table 1**. Then, the EF-KP was prepared as solution form to be administered in each experimental mouse.




FIG. 1: THE EF-KP CHROMATOGRAM AND THE POSITION OF RUTIN MARKER IN EF-KP (A) AND RUTIN STANDARD (B)




FIG. 2: THE STANDARD CURVE OF RUTIN STANDARD

TABLE 1: CALCULATION OF RUTIN MARKER IN THE EF-KP SAMPLE

Description sample	Internal Code	Calculated concentration (ug/L)	Dilution Factor	Calculated concentration (ug/kg)	Average calc conc (ug/kg)	Result (mg/kg)
EF-KP	1	133	100	13,300	13,400	13.4
	2	135		13,500		

The Analysis of L-selectin and the Related Markers: CD62L or L-selectin is a T regulatory marker. The flow cytometry analysis was performed simultaneously on CD4, CD8, and CD62L markers. The relative percentages of CD4⁺L-selectin⁺ and CD8⁺L-selectin⁺ T cells were calculated. The assessment of CD4:CD8 ratio was

done by using the flow cytometry assay. The results are shown in Table 2 and Fig. 3 - 5.

TABLE 2: THE RATIO OF CD4⁺: CD8⁺ T CELLS

Groups	CD4:CD8 Ratio
Negative control	3.78 : 1
EF-KP	3.51 : 1
Positive control	4.04 : 1




FIG. 3: THE RELATIVE PERCENTAGE OF CD4⁺CD8⁺ T CELLS AS A RESULT OF FLOW CYTOMETRY ANALYSIS OF THE FRESH SPLEEN OF THE THREE EXPERIMENTAL GROUPS

(a), EF-KP group (b), and positive control group (c) (n = 10 mice per group)

Then, the calculation result of the relative percentage of CD4⁺L-selectin⁺ T cells on each group is shown in Fig. 4. This result shows the increase of the percentage of CD4⁺L-selectin⁺ after 21 day administration of the EF-KP. This increase

is not significant, but it indicates an inhibition of naïve T-cell differentiation do not become the T cells effector. The flow cytometry analysis was continued to CD8⁺L-selectin⁺ T-cell parameter. The profile is shown in Fig. 5.




FIG. 4: THE RELATIVE PERCENTAGE PROFILE OF CD4⁺ L-SELECTIN⁺ T CELLS AS A RESULT OF FLOW CYTOMETRY ANALYSIS OF THE FRESH SPLEEN OF NEGATIVE CONTROL GROUP (a) EF-KP group (b) and positive control group (c) (n = 10 mice per group)




FIG. 5: THE RELATIVE PERCENTAGE OF CD8⁺L-SELECTIN⁺ T CELLS AS A RESULT OF FLOW CYTOMETRY ANALYSIS IN THE SPLEEN CELLS IN CONTROL NEGATIVE GROUP (a) EF-KP group (b), and positive control group (c) (n = 10 mice per group) *significantly different (p < 0.05) to negative and positive control groups

The CD8⁺L-selectin⁺ T cells are activation markers of CD8⁺ T cells (T cytotoxic). The significant elevation of CD8⁺L-selectin⁺ in spleen shows a reduction of circulated T cell cytotoxic. It prevents attachments of auto-antigens and non-self recognition.

The Total Leukocyte Count (TLC) Result: The TLC assay was performed after 2 week treatment. The blood was taken from the tail vein. The mice were kept alive during this procedure for the next treatment. The results are shown in Fig. 6.




FIG. 6: THE TOTAL LEUKOCYTES OF THREE EXPERIMENTAL GROUPS. (n=3 MICE PER GROUP) * Significantly different to the negative control group

This result shows a significant leukocytes reduction after the treatment. It indicates an anti-inflammatory effect and it is caused by the L-selectin regulation.

DISCUSSION: The EF-KP contains multiple compounds which are active as anti-inflammatory, immunosuppressant, and antioxidant. One of the active compounds quantitated for the quality control in this research was rutin, a flavonoid compound. According to the result on **Fig. 1**, the rutin compound was found in the retention time of 2.90. Based on a series concentration of rutin standard, the rutin measured in the EF-KP sample is 13.4mg/kg (**Table 1**). The limitation of the tandem system used was the precision of the molecular weight in the low retention time. It was resulted from the instrument validation which used a standard with the molecular weight of 500 Da. However, the limitation could be handled by comparing the spectrum with other previous publications about the active compounds of *Kalanchoe pinnata* (Lmk) Pers. Rutin, as one compound of flavonoids in this plant has also identified in other research^{18, 32, 33}.

After the treatment finished, the spleen of each mouse was isolated for the L-selectin⁺ T cells assay. CD62L or L-selectin is one of the T regulatory markers. Ermann³⁴ states that T regs CD4⁺CD25⁺ with the co-transfer of L-selectin⁺ is able to prevent tissue damage under the rejection of the immune system. This biomarker could be observed simultaneously by using flow cytometry method on the specific marker of CD4⁺CD8⁺L-selectin⁺. Normally, the mice have the ratio of CD4⁺ T cells two times higher than CD8 T cells.

In this research, the ratio of CD4:CD8 is shown in **Table 2**. The results show a mild reduction of the ratio in EF-KP group. Although it did not achieve the normal condition, this reduction was a good sign of the effectiveness of the active compounds in EF-KP as a complementary drug for lupus patients. The effective drugs that could balance the ratio of CD4:CD8 have not been found³⁴⁻³⁶. The balance of the ratio could reduce the auto-reactive cells and then keep the tissue and organ normal. The positive control group showed an opposite effect. The ratio increased higher than the negative control group. It was assumed that the cyclophosphamide used in

the positive control group had a toxic effect. It could be a consideration in the cyclophosphamide treatment. For further investigation, we observed the L-selectin⁺ marker.

L-selectin⁺ of T cells, a type 1 membrane protein, regulates lymphocyte homing into peripheral lymph node and accumulates leukocytes in inflammation area^{3, 8, 37}. This molecule is expressed by naïve T cells CD4⁺ L-selectin⁺ and CD8⁺ L-selectin⁺. The naïve T cells circulate in blood, spleen, and peripheral lymph node and then it is attached by antigen. As a result, the naïve T cells are activated when L-selectin⁺ is shedded. The L-selectin⁺ T cells are expressed more than 80% in the normal condition. On the unhealthy condition, the expression decreases and then the T cells are activated^{37, 38}.

This research results in the relative percentages of CD4⁺L-selectin⁺ which are shown in **Table 2**. The EF-KP treatment increases the relative percentage of CD4⁺CD25⁺. The value is about 1% but the statistic calculation results a non-significant value. It suggests that EF-KP is able to inhibit the differentiation of naïve T cells to be the T-cell effector. The role of L-selectin⁺ is as T-cell activation marker. CD4⁺ L-selectin⁺ T cells would be activated as CD4 T cells. The T-cell activation is avoided in autoimmune condition^{39, 40}. The auto-reactive T cells can attach the normal cells and tissues because of a wrong recognition of self-autoantigen. The reduction of the CD4⁺ T-cell activation reduces the immune complex formation. Auto-antigen that could not be eliminated by CD4 T cells will be attached by CD8 T cells.

The flow cytometry analysis results in the increase of the relative percentage of CD8⁺L-selectin⁺ T cells (**Table 3**). The relative percentage of CD8⁺L-selectin⁺ in the EF-KP group was 15.91%. It was more than two times higher than the negative control group. This increase is statistically significant. The high percentage of the EF-KP group and the positive control group shows the reduction of CD8⁺L-selectin⁺ T-cell differentiation. Thus, the CD8 T cell effector was reduced. This reduction is beneficial since the low number of CD8 has a direct impact on the reduction of CD8 T-cell reactivity^{37, 41}.

The low reactivity of CD8 T cell reduces the number of damage normal cells that are recognized as a non-self.

Total Leukocyte Count (TLC): The TLC assay was performed to prove the regulation of L-selectin⁺ that binds the naïve T cells that stayed in the lymphoid organs. After 2 week treatment, we took the mice blood from the tail veins. The results in **Table 4** show a significant reduction of leukocytes in the group that received EF-KP and cyclophosphamide. The reduction of the total leukocyte is associated with the reduction of an inflammation. It is consistent with anti-inflammatory effect of EF-KP reported by Ferreira¹⁹. This effect is benefit for lupus condition. The adhesion molecule L-selectin⁺ might play a role in this effect. However, further research is necessary to prove this suggestion.

CONCLUSION: The active compounds of EF-KP increase the L-selectin⁺ T cells mainly CD8⁺L-selectin⁺ T cells in the spleen cause the inhibition of T-cell activation in the lupus model.

ACKNOWLEDGEMENT: This research was funded by DIPA PNPB 2015 Faculty of Pharmacy Universitas Mulawarman (Grant number 1787/UN17.12/HK/2015), Hibah Penelitian Disertasi Doktor 2017 (Grant number: 025/E3.4/2017), and BPPDN Scholarship for Indonesian doctorate student (Grant number: 906.8/E4.4/2015).

CONFLICT OF INTEREST: We declare no conflict of interest.

REFERENCES:

1. Moulton VR, Suarez-fueyo A, Meidan E, Li H, Mizui M and Tsokos GC: Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. *Trends in Molecular Medicine* 2017; 23(7): 615–35.
2. Singh N, Kumar B, Aluri V and Lenert P: Interfering with baffled B cells at the lupus tollway: Promises, successes, and failed expectations. *Journal of Allergy and Clinical Immunology* 2015; 137(5): 1325–33.
3. Mohammed RN, Watson HA, Vigar M, Ohme J, Thomson A, Humphreys IR *et al.*: L-selectin is Essential for Delivery of Activated CD8⁺T Cells to Virus-Infected Organs for Protective Immunity. *Cell Reports* 2016; 14(4): 760–71.
4. Manrique SZ, Correa MAD, Hoelzinger DB, Dominguez AL, Mirza N, Lin H-H *et al.*: Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth. *Journal of Experimental Medicine* 2011; 208(7): 1485–99.
5. Dominguez-Luis M, Herrera-García A, Arce-Franco M,

- Armas-González E, Rodríguez-Pardo M, Lorenzo-Díaz F, *et al.*: Superoxide anion mediates the L-selectin down-regulation induced by non-steroidal anti-inflammatory drugs in human neutrophils. *Biochemistry and Pharmacology* 2013; 85(2): 245–56.
6. Bhavsar SK, Merches K, Bobbala D and Lang F: Biochemical and Biophysical Research Communications AKT / SGK-sensitive phosphorylation of GSK3 in the regulation of L-selectin and perforin expression as well as activation induced cell death of T-lymphocytes. *Biochemical and Biophysical Research Communication* 2012; 425(1): 6–12.
7. El-Samahy MH, Adly AAM, Ismail EA and Salah NY: Regulatory T cells with CD62L or TNFR2 expression in young type 1 diabetic patients: Relation to inflammation, glycemic control and micro-vascular complications. *Journal of Diabetes and its Complications* 2015; 29(1): 120–6.
8. Marilyn JT: Cellular adhesion and the Endothelium, E-Selectin, L-Selectin, and Pan-Selectin Inhibitors. *Hematology and Oncology Clinics of North America* 2014; 28: 341-354.
9. Rottman JB and Willis CR: Mouse models of systemic lupus erythematosus reveal a complex pathogenesis. *Veterinary Pathology* 2010; 47(4): 664–76.
10. Sang A, Zheng YY and Morel L: Contributions of B cells to lupus pathogenesis. *Molecular Immunology* 2014; 62(2): 329–38.
11. Marceau K, Ruttle PL, Shirtcliff EA, Essex MJ, Susman EJ, Studies A *et al.*: T cells as a therapeutic target in SLE. *Lupus* 2015; 24(0): 351–63.
12. Kasjmir Y, Handono K, Wijaya LK, Hamijoyo L, Albar Z, Kalim H *et al.*: Rekomendasi Perhimpunan Reumatologi Indonesia untuk Diagnosis dan Pengelolaan Lupus Erythematosus Sistemik 2011; 1-54.
13. Ziemer M and Milkova L: Lupus erythematosus Part II: Clinical picture, diagnosis and treatment. *Deutsche Dermatologische Gesellschaft* 2014; 1204: 285–302.
14. Fiechtner JJ and Montroy T: Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotrophic hormone: a single-site, open-label trial. *Lupus* 2014; 23(9): 905–12.
15. Thanou A and Merrill JT: Treatment of systemic lupus erythematosus: new therapeutics avenues and blind alleys. *Nature Reviews Rheumatology* 2014; 10: 23-34.
16. Zampeli E, Klinman DM, Gershwin ME and Moutsopoulos HM: A comprehensive evaluation for the treatment of lupus nephritis. *Journal of Autoimmunity* 2017; <http://dx.doi.org/10.1016/j.jaut.2016.12.011>.
17. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD *et al.*: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Research* 2012; 64(6): 797–808.
18. Bogucka-kocka A and Zidorn C: Phenolic acid content, antioxidant and cytotoxic activities of four *Kalanchoe* species. *Saudi Journal of Biological Sciences* 2016; <http://dx.doi.org/10.1016/j.sjbs.2016.01.037>.
19. Ferreira RT, Coutinho MAS, Malvar DDC, Costa EA, Florentino IF, Costa SS *et al.*: Mechanisms underlying the antinociceptive, antiedematogenic, and anti-inflammatory activity of the main flavonoid from *Kalanchoe pinnata*. *Evidence-based Complement of Alternative Medicine* 2014; dx.doi.org/10.1155/2014/429256.
20. Julius AI, Charles A, Samuel NE, Ansong AD, Mahmood S, Samuel A *et al.*: Nutraceutical with Anti-Inflammatory Activity for the Management of Airway Remodeling in

- Bronchial Asthma: *Kalanchoe integra* Var. Crenata (Andr.) Cuf Leaf Extract. Pharmacology and Pharmacy 2014; 5: 250–61.
21. Sari Y, Wahyuni R, Maya A, Syukur NA and Dewi ES: Immunomodulation Effects of *Bryophyllum pinnatum* on Pregnant Pristane-Induced Lupus Mice Model. Research Journal of Life Science 2016; 3(3): 190–200.
 22. Coutinho MA, Muzitano MF, Cruz EA, Bergonzi MC, Kaiser CR, Tinoco LW, Bilia AR, Vincieris FF, Rossi-Bergmann B and Costa SS: Flowers from *Kalanchoe pinnata* are a rich source of T cell-suppressive flavonoids. Natural Product Communications 7(2): 175-8.
 23. Ozolua, RI, Idogun SE and Tamafel GE: Acute and Sub-Acute Toxicological Assessment of Aqueous Leaf Extract of *Bryophyllum pinnatum* (Lam.) in Sprague-Dawley Rats. American Journal of Pharmacology and Toxicology 2010; 5(3): 145-151.
 24. Gwehenberger B, Rist L, Huch R and Von Mandach U: Effect of *Bryophyllum pinnatum* versus fenoterol on uterine contractility. European Journal Obstetry and Gynecology and Reproduction Biology 2004; 113(2): 164–71.
 25. Nascimento LBDS, Moreira NDS, Leal-Costa MV, Costa SS and Tavares ES: Induction of wound-periderm-like tissue in *Kalanchoe pinnata* (Lam.) Pers. (Crassulaceae) leaves as a defence response to high UV-B radiation levels. Annals of Botany 2015; 116(5): 763–9.
 26. Furer K, Simoes-Wust AP, Von Mandach U, Hamburger M and Poterat O: *Bryophyllum pinnatum* and related species used in anthroposophic medicine: Constituents, Pharmacological Activities, and Clinical Efficacy. Planta Medica 2016; 82(11–12): 930–41.
 27. NRC: Guide of the Care and Use of Laboratory Animal 2011; 46: 267-268.
 28. Indriyanti N, Soeroso J and Khotib J: The immunosuppressant effect comparison between ethyl acetate and n-butanol fractions of *Kalanchoe pinnata* (Lmk) Pers in 2, 6, 10, 14-tetramethylpentadecane. Journal of Tropical Pharmacy and Chemistry 2017; 4(1): 7-13.
 29. Leiss H, Niederreiter B, Bandur T, Schwarzecker B, Blüml S, Steiner G et al.: Pristane-induced lupus as a model of human lupus arthritis: evolvement of autoantibodies, internal organ and joint inflammation. Lupus 2013; 22(8): 778–92
 30. Lin Y, Yan Y, Zhang H, Chen Y, He Y, Wang S et al.: Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice. Acta Pharmaceutica Sinica B 2016; 7(2): 159–66.
 31. Zhu W, Xu J, Jiang C, Wang B, Geng M, Wu X et al.: Pristane induces autophagy in macrophages, promoting a STAT1-IRF1-TLR3 pathway and arthritis. Clinical Immunology 2017; 175: 56–68.
 32. Nascimento LBDS, Leal-Costa MV, Menezes EA, Lopes VR, Muzitano MF, Costa SS et al.: Ultraviolet-B radiation effects on phenolic profile and flavonoid content of *Kalanchoe pinnata*. Journal of Photochemistry and Photobiology 2015; 148: 73–81.
 33. Milad R, El-ahmady S and Singab AN: Genus *Kalanchoe* (Crassulaceae): A Review of Its Ethnomedicinal, Botanical, Chemical and Pharmacological Properties. European Journal of Medicinal Plants 2014; 4(1): 86–104.
 34. Ermann J, Hoffmann P, Edinger M, Dutt S, Blankenberg FG, Higgins JP et al.: Only the CD62L⁺ subpopulation of CD4⁺CD25⁺ regulatory T cells protects from lethal acute GVHD. Blood 2005; 105(5): 2220–6.
 35. Matta MC, Soares DC, Kerstenetzky MS, Freitas ACP, Kim CA and Torres LC: CD4⁺CD25^{high}Foxp3⁺ Treg deficiency in a Brazilian patient with Gaucher disease and lupus nephritis. Human Immunology 2016; 77(2): 196–200.
 36. Maldonado A, Mueller YM, Thomas P, Bojczuk P, O'Connors C and Katsikis PD: Decreased effector memory CD45RA⁺ CD62L⁻ CD8⁺ T cells and increased central memory CD45RA⁻ CD62L⁺ CD8⁺ T cells in peripheral blood of rheumatoid arthritis patients. Arthritis Research and Therapy 2003; 5(2): 91–6.
 37. Hirata T, Usui T, Kobayashi S and Mimori T: A novel splice variant of human L-selectin encodes a soluble molecule that is elevated in serum of patients with rheumatic diseases. Biochemical Biophysical Research Communication 2015; 462(4): 371–7.
 38. Bengtsson A, Pettersson Å, Wichert S, Gullstrand B, Hansson M, Hellmark T et al.: Low production of reactive oxygen species in granulocytes is associated with organ damage in systemic lupus erythematosus. Arthritis Research and Therapy 2014; 16(3): R120.
 39. Lu MC, Lai NS, Chen HC, Yu HC, Huang KY, Tung CH et al.: Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immune pathogenesis. Clinical and Experimental Immunology 2013; 171(1): 91–9.
 40. Zhang Y, Zhao M, Sawalha AH, Richardson B and Lu Q: Impaired DNA methylation and its mechanisms in CD4⁺T cells of systemic lupus erythematosus. Journal of Autoimmunity 2013; 41: 92–9.
 41. Shah D, Sah S and Nath SK: Interaction between glutathione and apoptosis in systemic lupus erythematosus. Autoimmunity Reviews 2013; 12(7): 741–51.

How to cite this article:

Indriyanti N, Soeroso J and Khotib J: T-cell activation controlling effects of ethyl acetate fraction of *Kalanchoe pinnata* (lmk) pers on tmpd-treated lupus mice. Int J Pharm Sci Res 2018; 9(2): 475-82. doi: 10.13040/IJPSR.0975-8232.9(2).475-82.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to ANDROID OS based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)



INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH

Inclusion in Web of Science (Thomson Reuters) - ESCI

Projected Impact Factor (2017): 0.59 , SJR (2017): 0.137

Five-Year Projected Impact Factor: 1.83



[Editorial Board](#) [Current Issues](#) [Archives](#) [Instructions to Authors](#) [Manuscript Submission](#) [Conference Proceedings](#)

[Home](#) [Editorial Board](#)

Editorial Board

EDITOR-IN-CHIEF

Dr. Shashi Alok
Assistant Professor, Institute of
Pharmacy, Bundelkhand University
Jhansi (U.P.), India

MANAGING EDITOR

Mrs. Monika Sabharwal
Managing Editor, International Journal
of Pharmaceutical Sciences and
Research, Panchkula (HR), India

INTERNATIONAL ADVISORY BOARD MEMBERS

Dr. Raymond. C. Jagessar
Department of Chemistry, University of
Guyana Faculty of Natural Sciences,
South America

Prof. (Dr) G. K. Dash
Faculty of Pharmacy & Health Science,
University Kuala Lumpur, Perak ,
Malaysia

Prof. (Dr) J.O.C. Silva Junior
School of Pharmacy, Federal University
of Para Belem, Para, Brazil

Prof. (Dr) Mohamed Abdel Hamid
Professor of Pharmaceutical Chemistry
& Former Dean of Faculty of Pharmacy,
Ain Shams University, Cairo, Egypt

Dr. Narazah Mohd Yusoff
Advanced Medical and Dental Institute,
University Sains Malaysia Kepala
Batas, Pulau Pinang, Malaysia

Dr. Sandeep Chaudhary
Institute of Microbial Chemistry
Microbial Chemistry Research
Foundation, Kamiosaki, Shinagawa-Ku,
Tokyo, Japan

Dr. Mayank Thakur
Charite University of Medicine,
Benjamin Franklin Campus,
Hindenburgdamm, Berlin, Germany

Dr. Satya Dev Sharma
Cancer Research Scientist,
R.P.C.I., Buffalo, New York, USA

Dr. S.H. Yuliani
Faculty of Pharmacy, Gadjah Mada
University, Sekip Utara Yogyakarta,
Indonesia

Dr. Havagiray R. Chitme
Professor, Oman Medical College
Muscat, Sultanate of Oman

Dr. Mohd. Sohail Akhtar
Department of Pharmacognosy, School
of Pharmacy, University of Nizwa,
Sultanate of Oman

Dr. S. Palani
School of pharmacy, 7th October
university, Misruta, Libya

Dr. Nisha Josheph
School of Pharmacy, College of Health
Sciences, Mekelle University, Mekelle,
Ethiopia

Dr. Roman Paduch
Maria Curie- Sklodowska University,
Lublin, Poland

Md. Hemayet Hossain
Senior Scientific Officer Chemical
Research Division , (BCSIR), Dhaka,
Bangladesh

Prof (Dr.) Lawrence H. Block
Division of Pharmaceutical Sciences
437 Mellon Hall, Duquesne University
Pittsburgh, PA

Dr. Rakesh Tekade
University of Central Lancashire
Preston, England, UK

Gaurav Sharma
Department of Pharmaceutical
Sciences, Idaho State University
Pocatello, USA

Dr. M.A.M Oshi
Faculty of Pharmacy, Omdurman
Islamic University, Omdurman, Sudan

Dr. Md. A. A. El Aziz Aly El Degwy
Formulation section head, Mepaco
Pharmaceutical Company, Maadi,
Cairo, Egypt

Dr. Shankar Jothi
Faculty of Science, Technology & Engg.
La Trobe University, Australia

Dr. Siddharthya Mujumdar
Boehringer Ingelheim Pharmaceuticals
Inc, Ridgebury Rd, Ridgefield, CT, USA

Dr. Rajesh G Katare
Department of Physiology Otago
School of Medical Sciences University
of Otago, New Zealand

Mr. Nipun Mahajan
School of Chemistry National
University of Ireland Galway, Ireland

Dr. Prabhakar Reddy Polepally
Institute of Pharmaceutical Sciences
University of Mississippi, MS, USA

Dr. Shruti Rawal
Postdoctoral Fellow, NYU Langone
Medical Center, New York, USA

Dr. Prasoon Gupta
Scientist, Florida Atlantic University
Boca Raton, FL, USA

Dr. Shahenda M. El-Messery
Department of Pharmaceutical organic
Chemistry, Mansoura University,
Mansoura, Egypt

Dr. Shivanand Puthli
Principal Scientist, TrisPharma Inc.,
New Jersey, USA.

Dr. Ravi S Shukla
Scientist III, Amneal Pharmaceuticals
LLC, Brookhaven, New York, USA

Dr. Prity Tomar
London, United Kingdom

Dr. Shivkanya Fuloria
Faculty of Pharmacy, AIMST University,
Semeling Campus, Bedong, Kedah
Darul Aman, Malaysia

Dr. Mohammad Reza Abedi
Department of Applied Chemistry
Islamic Azad University, Quchan
Branch (IAUQ), Quchan, Khorasan
razavi, Iran.

Dr. Srinivasan Shanmugam
Project Leader, Formulation R&D,
Hanmi Pharm. Co. Ltd., Hwasung-Si,
Gyeonggi-Do, South Korea

Dr. Sunita Subramanian
Rollins Research Centre, Department
of Biochemistry, Emory University
School of Medicine, Atlanta, GA, USA

Dr. Bhagwat Prasad
Department of Pharmaceutics,
University of Washington Seattle,
Washington, USA

Dr. Surendra Kumar Jain
National Center for Natural Products
Research School of Pharmacy,
University of Mississippi University,
USA.

Dr. Pushkar M. Kulkarni
Department of Pharmaceutical
Sciences, Bouve College of Health
Sciences, Northeastern University,
Boston, MA, USA

Dr. Monika Sharma
Postdoctoral Fellow, NYU Langone
Medical Center, New York, USA

Sameer Sachdeva
Research Scientist II, Amneal
Pharmaceuticals, NJ, USA

Dr. Ahmed S. Zidan
Center of drug evaluation and
research, Food and Drug
Administration, USA

Dr. Anekant Jain
United States of America

Dr. Animikh Ray
School of Pharmacy, University of
Missouri Kansas City (UMKC), USA

Dr. Javad Sharifi Rad
Department of Pharmacognosy Faculty
of Pharmacy Zabol University of
Medical Sciences Zabol, Iran

Dr. Chellappan Dinesh Kumar
Department of Life Sciences, School of
Pharmacy, International Medical
University, Kuala Lumpur, Malaysia

Dr. Ajaykumar N. Sharma
The University of Texas Health Science
Center, Houston, Texas, USA

Dr. Chin Jin Han
Department of Pharmaceutical
Chemistry, Faculty of Pharmaceutical
Sciences, UCSI University, Cheras,
Kuala Lumpur, Malaysia

Dr. Alptug Atila
Department of Analytical Chemistry,
Faculty of Pharmacy, Ataturk
University, Erzurum, Turkey

Dr. Gyanendra Singh
School of Medicine, Louisiana State
University Health Sciences Center New
Orleans, USA

CONSULTANT EDITORS

Dr. Prabodh Shukla

Assistant Professor, UPRIMS & R, Safai
Medical College, Safai, Etawah (U.P.),
India

Dr. Padmini Shukla

Assistant Professor, UPRIMS & R, Safai
Medical College, Safai, Etawah (U.P.),
India

Dr. Ramesh Sabharwal

Medical Officer, LNJP, Kurukshetra
(Haryana), India

Dr. (Mrs.) Sanju Nanda

Department of Pharmaceutical Sciences
M. D. University, Rohtak (Haryana), India

Prof. (Dr.) Amita Verma

Department of Pharmaceutical Sciences,
SHIATS, Allahabad (U.P.), India

Dr. Kuldeep Singh

Faculty of Pharmacy, Integral University,
Lucknow (U.P.), India

Dr. Ajay Gupta

Department of Pharmacy, Chatrapati
Sahu Ji Maharaj University, Kanpur, (U.
P.), India

Dr. Shanti Bhushan Mishra

United Institute of Pharmacy, Allahabad
(U.P.), India

EXECUTIVE EDITORS

Prof. (Dr.) Sanjay Jain

Smriti College of Pharmaceutical
Sciences, Indore (M. P.), India

Prof. (Dr) B. Gopalakrishna

R.R. College of Pharmacy, Bangalore
(Karnataka), India

Prof. (Dr) A. R. Kulkarni

Department of Pharmacology, SETS
College of Pharmacy, Dharwad
(Karnataka), India

Prof. (Dr) Vimal Jain

Institute of Pharmacy Nirma University,
Ahmadabad (Gujarat), India

Prof. (Dr) A. K. Gujjar

Institute of Pharmacy, Nirma University,
Ahmadabad (Gujrat), India

Prof. (Dr.) Arun Nanda

Dean, Faculty of Pharmaceutical Sciences
M.D. University, Rohtak (Haryana), India

Prof. (Dr.) S. K. Prajapati

Institute of Pharmacy, Bundelkhand
University, Jhansi (U.P.), India

Dr. S. K. Jain

Institute of Pharmacy, Bundelkhand
University, Jhansi (U.P.), India

ASSOCIATE EDITORS

Prof. (Dr.) Shivesh Jha

Department of Pharmaceutical Sciences,
BIT, Mesra, Ranchi (Jharkhand), India

Dr. K. P. Namdev

Guru Ghasidas Vishwavidhyalaya,
Bilaspur (Chhattisgarh), India

Dr. (Mrs.) Savita Vyas

Department of Pharmacology, MGM
Medical College, Indore (M. P.), India

Dr. Kumud Upadhyaya

GIS Institute of Professional Studies,
Dehradun, Uttarkhand, India

Dr. Abhishek Mathur

Research Scientist (R&D) Sheetal Life
Sciences, Dehradun (U.K), India

EDITORIAL BOARD

Prof. (Dr.) Ranjit Singh

Ex. Pro-Vice Chancellor, Shobhit
University, Meerut (U. P.), India

Dr. Ashutosh Mishra

Principal, A.N.D. College of Pharmacy,
Bahnan, Gonda (U.P.), India

Dr. Asif Husain

Department of Pharmaceutical
Chemistry Faculty of Pharmacy,
Hamdard University (Jamia Hamdard),
New Delhi-110062

Dr. Vinod Kumar Tiwari

Department of Chemistry, Centre of
Advanced Study, Banaras Hindu
University Varanasi (U.P), India

Dr. N. K. Tiwari

Thakral College of Technology, Oriental
group of Institute, Bhopal (M. P.), India

Prof. (Dr.) Tejal A. Mehta

Institute of Pharmacy Nirma University,
Ahmadabad (Gujrat), India

Dr. R. Irchhaiya

Dr. Sushil K. Kashaw

Dr. R. N. Gupta

Department of Pharmacognosy, Institute of Pharmacy, Bundelkhand University, Jhansi (U.P.), India

Dr. Subha Ganguly

Faculty of Fishery Sciences, West Bengal University of Animal and Fishery Sciences, Kolkata, India

Dr. Mahesh Gupta

Principal Kota College of Pharmacy, Kota (Rajasthan), India

Mr. Rahul Taneja

Department of Science & Technology, Government of Haryana, Panchkula (H.R.), India

Mr. Vivekanand Katare

Vivekanand College of Pharmacy Bhopal (M. P.), India

Dr. Lavkush Dwivedi

Institute of Biomedical Sciences Bundelkhand University, Jhansi (U.P.), India

Mr. Sourabh Kosey

Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, India.

Mrs. Monika Pandey

Mahatma Gandhi College of Pharmaceutical Sciences, Jaipur (Rajasthan), India

Mr. V. K. Singh

Institute of Pharmacy, Bundelkhand University, Jhansi (U.P.), India

Mrs. Anuradha Singh

Institute of Pharmacy, Shree Ganpati Institute of Technology, Ghaziabad (UP), India

Dr. Jagbir

BPS Govt. Medical College for Women, Khanpur Kalan, District - Sonapat, Haryana, India

Dr. Saurabh Satija

Assistant Professor, School of Pharmaceutical Sciences, Lovely Professional University, Punjab, India

Department of Pharmaceutical Sciences, Dr. H S Gour Central University, Sagar (M. P.), India

Dr. Amrisha Chandra

Institute of Biomedical Education & Research, Manglayatan University, Beswan, Aligarh (U.P.), India

Dr. Himanshu Pandey

Department of Pharmacy, SHIATS, Allahabad (U.P.), India

Dr. Rohit Goyal

Department of Pharmacology, Shoolini University, Solan, (H.P.), India

Dr. Prem Prakash Singh

Institute of Pharmacy, Bundelkhand University, Jhansi (U.P.), India

Dr. Ramesh Singh

Department of Pharmacy Rameshwaram Institute of Tech. & Management Lucknow (U.P.), India

Dr. Aviral Jain

Adina Institute of Pharmaceutical Sciences Sagar (M.P.), India

Mr. Shobhit Singh

Institute of Pharmacy, Bundelkhand University Jhansi (U.P.), India

Mr. Piyush Mantri

Acropolis Institute of Technology & Research Indore (M.P.), India

Mr. Ramesh Chand

Aerosol Scientist and Chemist/Senior Research Associate Lovelace Respiratory Research Institute Albuquerque, NM, USA

Mr. Rahul Deo Yadav

Motilal Nehru Medical College, Allahabad (U.P.), India

Dr. Meenu Mehta

Assistant Professor, School of Pharmaceutical Sciences, Lovely Professional University, Punjab, India

Department of Pharmaceutical Sciences, BIT, Mesra, Ranchi (Jharkhand), India

Dr. Sukhbir Lal Khokra

Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra (Haryana), India

Dr. Nitesh Kumar

Department of Pharmacology & Toxicology, College Of Veterinary Science & Animal Husbandry, Kuthulia, Rewa (M.P.), India

Mr. Man Singh

Government medical college, Allahabad (U.P.), India

Dr. Anurag Khatkar

Dept. of Pharmaceutical Sciences M.D.University, Rohtak (Haryana), India

Ms. Preeti Bohra

Research Scientist Ranbaxy Laboratories Ltd. Mohali (Punjab), India

Dr. Pankaj Shukla

Department of Chemistry, Research lab, D.B.S. College Kanpur (U.P.), India

Mr. Devendra Singh

Institute of Pharmacy, Bundelkhand University, Jhansi (U.P.), India

Dr. Puspendra Kumar

Assistant Professor Department of Pharmaceutical Sciences Krishna Institute of Engineering and Technology Ghaziabad, Uttar Pradesh, India

Dr. Rupesh K. Gautam

Associate Professor, Department of Pharmacology, ADINA Institute of Pharmaceutical Sciences, Sagar (M.P.), India

Dr. Neelesh Malviya

Smriti College of Pharmaceutical Education, Indore (M.P.), India

PUBLICATION COMMITTEE MEMBERS

Dr. Pragati Saini
Lucknow (U.P.), India

Dr. S. Rajvaidya
Bhopal (M.P.), India

Mr. Vimal Yadav
Jaunpur (U.P.), India

Dr. Namrata Singh
Nagpur (M.H.), India

Mr. Ashish Mishra
Kanpur (U.P.), India

Mr. Dherendra Goswami
Jhansi (U.P.), India

Mr. Gautam Verma
Gonda (U.P.), India

Ms. Neha Sharma
Bhopal (M.P.), India

CONTENT MANAGEMENT

Mr. Aman Santosh
Lalitpur (U.P.), India

Mrs. Swati Jain
Ghaziabad (U.P.), India

Mrs. Archana Ojha
Ghaziabad (U.P.), India

Mr. Sumit Kant Sinha
Lucknow(U.P.) , India

Mrs. Noopur Pandey
Vadodara (Gujrat), India

Mr. Dilip Kumar Chanchal
Jhansi, (U.P.), India

Mr. Rohit Kumar Bijauliya
Jhansi, (U.P.), India

INTERNATIONAL CONFERENCE, MALAYSIA – 2018

Conference proceedings of International conference of pharmacy & health sciences will be published in IJPSR, organized by Faculty of Pharmacy and Health Sciences, University Kuala Lumpur, Ipoh, Peark, Malaysia, between 14-16th September 2018.

CiteScore (2017) : 0.27

SJR (2017) : 0.137

0.27 ²⁰¹⁷
CiteScore
Powered by Scopus

